Heron Therapeutics enters supply agreement with Patheon and Thermo Fisher
Investing.com - Hillenbrand (NYSE: HI) reported first quarter EPS of $0.56, $0.02 better than the analyst estimate of $0.54. Revenue for the quarter came in at $707M versus the consensus estimate of $695.56M.
Guidance
Hillenbrand sees Q2 2025 EPS of $0.53-$0.58 versus the analyst consensus of $0.64.
Hillenbrand sees FY 2025 EPS of $2.45-$2.80 versus the analyst consensus of $2.95.
Hillenbrand’s stock price closed at $33.95. It is up 9.41% in the last 3 months and down -23.48% in the last 12 months.
Hillenbrand saw 1 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Hillenbrand’s stock price’s past reactions to earnings here.
According to InvestingPro, Hillenbrand’s Financial Health score is "fair performance".
Check out Hillenbrand’s recent earnings performance, and Hillenbrand’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar